Enabling pre-clinical program of NEW Chemical Entities (NCEs) and providing one stop solution to customize the product in rapid phase. The activities recorded in the electronic lab notebook enforces online documentation in accordance to principles of ALCOA+. Our value proposition: Discovery Research Quick access to the building blocks and key intermediates Time is essence of synthesis Enable the supply for discovery research 100g to few kilos
Early phase development Quick access to Drug substance for toxicology studies Phase appropriate PRD to enable the scale up Non GMP facility: Flexible operation and accelerated delivery
Infrastructure
- 300+ fume hoods
- Kilo lab with cylindrical reactor varying 5L to 50L capacity
- Reactors from 500 L to 5000 L in Hyderabad & Bangalore
- 50L autoclave a with 20kg/Cm2 design pressure
- Pressure Nutsche filter, vaccum tray dryer and 20L rotavapor for downstream process
- Huber unit to operate the process -20 to 150 degree Celsius
- Internal network of strategic business partners
- We also have a potent kilo lab
Scientific Expertise
- Qualified PhDs and Postdocs in organic chemistry
- 150+ scientists in chemistry and analytical services
- 10+ process engineers and process safety engineers
Chemistry Capabilities
Expertise in
- Metal promoted cross coupling reaction
- Halogenation reactions
- High pressure hydrogenation
- Metal hydrate reactions
- Carbohydrates
- Lipids
- Peptides
- PEGylation
- Asymmetric synthesis
- Deuterated compound
- Heterocyclic chemistry
- Asymmetric hydrogenation
- Chiral synthesis
Analytical Capability
- High-performance liquid chromatography with varying detectors
- Gas chromatography
- Mass triple quad, 1H NMR Bruker
- Differential scanning calorimeter
- Micro calorimeter
- Reaction calorimetry
Why Aurigene Pharmaceutical Services?
Quick turnaround of sample delivery
A strong scientific and analytical team
Infrastructure for mg to kg synthesis
Large network of qualified strategic business partners
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Development and Kilo Lab
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence bypass central thymic tolerance. The success of immune checkpoint blockade...
Read More
Peptide Development and Manufacturing
Peptides are short chains of amino acids that are linked by peptide bonds. Several peptides linked together are called polypeptides. A protein contains one or more polypeptides. Therefore, proteins are long chains of amino acids held together by peptide bonds....
Read More
Biologics Process Scale-up Services
Built on a solid platform of development and manufacturing scientist, we enable scale up doe both upstream and downstream processes. ...
Read More
Expediting early development through innovative precision capsule filling technology
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...
Read More
Revisiting the reaction of b-chloroacroleins with 2-aminophenol: a new observation
2008
The reaction of b-chloroacrolein with 1 equiv of 2-aminophenol in DMF proceeds smoothly to afford 11-hydroxy derivative of chromenoquinoline in good yield. This single pot method allows for a rapid access to a variety of chromenoquinolines or oxepinoquinolines depending on the nature of b-chloroacrolein used. The structures were established by spectroscopic data ...
Read More-
Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2005
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More -
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.